Prostate cancer gene therapy.
Numerous gene therapy trials in the United States and throughout the world using various strategies are in progress for the treatment of locally advanced and metastatic prostate cancer. Although vector technology advances at a rapid pace, progress in elucidating the molecular pathways critical for the development and progression of prostate cancer has been slower and more deliberate. Thus far, prostate gene therapy appears to be safe and well tolerated. Through these early clinical trials, the safety and efficacy of gene therapy alone or in combination with more conventional therapy as a basis for the treatment of prostate cancer will ultimately be determined.
Steiner
Mitchell S
MS
Department of Urology, University of Tennessee Memphis, 1211 Union Avenue, Suite 340, Memphis, TN 38104, USA. msteiner@utmem.edu
Gingrich
Jeffrey R
JR
Chauhan
Ravi D
RD
D000256:Adenoviridae / Q000235:genetics; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003131:Combined Modality Therapy; D018390:Gene Targeting / Q000379:methods; D018014:Gene Transfer Techniques / Q000639:trends; D016147:Genes, Tumor Suppressor; D015316:Genetic Therapy / Q000379:methods* / Q000639:trends; D005822:Genetic Vectors / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000379:methods / Q000639:trends; D008297:Male; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000235:genetics / Q000628:therapy*; D014481:United States / Q000453:epidemiology
D019496:Cancer Vaccines